KCT0008219进行中（未招募）未知
A 12-week, Multi-center, Randomized, Double-blind, Placebo-Controlled Clinical Trial for the Evaluation of the Efficacy and Safety of MPCO on Mild Cognitive Impairment
INE B0 个研究点目标入组 150 人开始时间: 待定最近更新:
试验速览
- 阶段
- 未知
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 150
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional Study
入排标准
- 年龄范围
- 55(Year) 至 85(Year)（—）
- 性别
- All
入选标准
- •1) Men and women over 55 years old and under 85 years old
- •2) Those who can read Korean
- •3) A person whose memory score on CERAD-K decreased by more than 1.0 SD compared to the same education level and age group
- •4) A person who agreed to participate in this human application test before the human application test started and filled out the informed consent form
排除标准
- •1) Those currently undergoing treatment for severe immune system, respiratory system, gastrointestinal/liver and biliary system, kidney and urinary system, nervous system, musculoskeletal system, infectious diseases and malignant tumors You can participate at your discretion.)
- •2) Persons with mental illness such as depression, schizophrenia, alcoholism, drug dependence, etc.
- •3) Those with diseases accompanied by cognitive decline, such as dementia or Parkinson's
- •4) Those with a history of head trauma accompanied by loss of consciousness, cardiovascular disease (angina pectoris, myocardial infarction, transient ischemic attack, acute stroke, etc.) within 6 months of visit 1
- •5) Persons who have received estrogen replacement therapy within 2 months of visit 1
- •6) Those who have administered drugs (antipsychotics, drugs for degenerative diseases, brain function improvers, tricyclic antidepressants) that affect cognitive function within 4 weeks of visit 1
- •7) Those who have taken health functional foods related to cognitive function improvement within 2 weeks of visit 1
- •8) A person whose daily dose of vitamin E preparation is 400 IU or more or who is expected to not be able to reduce the dose
- •9) Thyroid disease patients with TSH of 0.1 or less or 10 or more
- •10) A person whose creatinine is twice the upper limit of normal at the implementing institution
- •11) A person whose AST or ALT is more than three times the upper limit of the implementing agency
- •12) Patients with uncontrolled hypertension
- •13) Patients with uncontrolled diabetes
- •14) Pregnant or lactating women or those who plan to become pregnant during this human application test
- •15) Those who are sensitive or allergic to food ingredients for this human application test
- •16) Those who have participated in other interventional clinical trials within 3 months of the start of this human application trial, or plan to participate in other interventional clinical trials after the start of this human application trial
- •17) Those who are judged unsuitable by the tester for other reasons
研究者
相似试验
已完成
2 期
Efficacy and Safety of BGG492 as Adjunctive Treatment in Patients With Partial Onset SeizuresCTRI/2010/091/001213ovartis Health care Private Limited126
招募中
不适用
A 12-week, Multi-center, Randomized, Double-blind, Placebo-Controlled Clinical Trial for the Evaluation of the Efficacy and Safety of DKB-140 on Gingival HealthKCT0009501Dong Kook Pharm120
已完成
不适用
A 12-week, Multi-center, Randomized, Double-blind, Placebo-Controlled Clinical Trial for the Evaluation of the Efficacy and Safety of HUN2-483 on Cognitive Function ImprovementKCT0009401Huons100
招募中
Unknown
Evaluation of the Efficacy and Safety of Kaempferia parviflora extract on Body FatEndocrine, nutritional and metabolic diseasesKCT0009398Dong-A University Hospital100
招募中
不适用
A 12-week, Multicenter, Randomized, Double-blind, Placebo-Controlled Clinical Trial for the Evaluation of the Efficacy and Safety of KBL982 on Improving Alcoholic Liver DysfunctioKCT0006987Kobiolabs105